Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Antibióticos para las exacerbaciones de la enfermedad pulmonar obstructiva crónica

Esta versión no es la más reciente

ver la versión actual 29 octubre 2018

Información

DOI:
https://doi.org/10.1002/14651858.CD010257Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 12 diciembre 2012see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Vías respiratorias

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Daniela J Vollenweider

    Correspondencia a: General Internal Medicine, John Hopkins University, Baltimore, USA

    [email protected]

    [email protected]

  • Harish Jarrett

    Department of Internal Medicine, Temple University Hospital, Philadelphia, USA

  • Claudia A Steurer‐Stey

    Institute of General Practice, University of Zurich, Zurich, Switzerland

  • Judith Garcia‐Aymerich

    Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain

    Hospital del Mar Research Institute (IMIM), Barcelona, Spain

    CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

    Department of Experimental and Health Sciences, University of Pompeu Fabra, Barcelona, Spain

  • Milo A Puhan

    Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

Contributions of authors

All authors conceived the idea for the review and wrote the protocol.
DV, HJ and CSS contributed towards the following: trial selection, data and trial characteristics extraction.

MAP, JGA, DV checked the data extraction.

DV and MAP contributed to trial grading.

DV wrote the first draft and all authors critically reviewed the draft.

DV and MP are the guarantors for this review.

Declarations of interest

Claudia Steurer‐Stey has lectured for the antibiotic‐producing companies AstraZeneca, GlaxoWellcome, Merck Sharp & Dome, Pfizer and Novartis. The remaining four authors (DV, HJ, JGA and MAP) do not have any known conflicts of interest.

Acknowledgements

We are grateful for support from staff of the Cochrane Airways Group, namely Emma Welsh (Managing Editor) and Elizabeth Stovold (Trials Search Co‐ordinator). We would also like to thank JL Alonso Martinez, AF Jørgensen, AP Sachs and Dr F Blasi for responding to our requests for further information about their studies.

Version history

Published

Title

Stage

Authors

Version

2018 Oct 29

Antibiotics for exacerbations of chronic obstructive pulmonary disease

Review

Daniela J Vollenweider, Anja Frei, Claudia A Steurer‐Stey, Judith Garcia‐Aymerich, Milo A Puhan

https://doi.org/10.1002/14651858.CD010257.pub2

2012 Dec 12

Antibiotics for exacerbations of chronic obstructive pulmonary disease

Review

Daniela J Vollenweider, Harish Jarrett, Claudia A Steurer‐Stey, Judith Garcia‐Aymerich, Milo A Puhan

https://doi.org/10.1002/14651858.CD010257

Differences between protocol and review

We had to change our primary outcome from treatment failure within two weeks to four weeks because the reporting of the time of the end point was too heterogeneous.

Some outcomes were not reported at all (hospital admission, admission to an ICU).

We did not analyse subgroups on duration of antibiotic intervention or type of antibiotic intervention because the number of studies was too small.

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.